Concepedia

Author

Neeraj Agarwal

Huntsman Cancer InstituteORCID

Also Known As

Agarwal N, Agarwal, Neeraj, Catherine Tangen, Gardner, Jerry, Irwin, Michael R., N Agarwal, N. Agarwal, Neeraj Agarwal, Neeraj Agarwal#, Nilesh Agarwal

999

Publications

21.1K

Citations

62

H-Index

113

Concepts

All Affiliations

Huntsman Cancer InstituteUniversity of UtahCity of HopeFred Hutch Cancer CenterUniversity of Michigan
NA

About

Neeraj Agarwal is an author at Huntsman Cancer Institute specializing in medicine, urology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

33

88

5.8K

2

Health Sciences

14

18

398

3

Public Health

4

4

1.8K

4

Engineering

1

1

11

5

Biostatistics

1

1

17

Neeraj Agarwal

×

204

Publications

17.9K

Citations

58

H-Index

YearCitations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi,

New England Journal of Medicine

2020

2.1K

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah,

The Lancet

2020

1.8K

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N., Neeraj Agarwal, Anders Bjartell,

New England Journal of Medicine

2019

1.4K

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Joaquı́n Mateo, Karim Fizazi,

New England Journal of Medicine

2020

734

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal,

Journal of the National Comprehensive Cancer Network

2022

627

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak,

Journal of Clinical Oncology

2021

507

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair J. Beard,

Journal of the National Comprehensive Cancer Network

2009

470

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Kim N., Simon Chowdhury, Anders Bjartell,

Journal of Clinical Oncology

2021

469

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles,

The Lancet

2023

453

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

Amir Goldkorn, Benjamin Ely, David I. Quinn,

Journal of Clinical Oncology

2014

329

Page 1